Drug Type Oligonucleotide |
Synonyms DLN-200, DLN-200 |
Target |
Action- |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date (02 Oct 2024), |
Regulation- |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Cardiovascular Diseases | - | 03 Oct 2024 |





